A human amygdala site that inhibits respiration and elicits apnea in pediatric epilepsy.
Ariane E Rhone, Christopher K Kovach, Gail Is Harmata...
https://pubmed.ncbi.nlm.nih.gov/32163374/Actively Recruiting
Led by Vanderbilt University Medical Center · Updated on 2026-06-11
40
Participants Needed
1
Research Sites
N/A
Total Duration
Researchers are investigating whether exposure to rose scent can help reduce the risk of Sudden Unexpected Death in Epilepsy SUDEP in adults with epilepsy. SUDEP is thought to be related to breathing problems during seizures, but the exact cause is unclear. This early phase 1 study aims to better understand how rose scent might influence seizure-related breathing issues in patients admitted for epilepsy monitoring. Participants will undergo two 24-hour periods of observational EEG monitoring during their hospital stay. The first 24 hours involve routine EEG monitoring without scent exposure, while the second 24 hours include continuous rose scent diffusion in the room using an essential oil diffuser. Throughout both periods, participants will wear a respiratory monitoring belt to measure breathing. Additional assessments include smell identification tests at the start and mood questionnaires before and after scent exposure. Participants will provide informed consent and take part in smell recognition testing and mood surveys. They will undergo continuous EEG and respiratory monitoring for 48 hours during their hospital stay, with 24 hours of exposure to rose scent in the second half. Researchers will measure the number of seizure and apneic episodes, mood changes, and respiratory function. The total study time is 48 consecutive hours with no restrictions on daily activities except wearing the respiratory belt.
CONDITIONS
Effect of Rose Odor Exposure on Ictal Apnea
B
Brigitte Jia, BA
W
William P Nobis, MD, PhD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Vanderbilt University Medical Center
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Rose scent exposure (2-phenylethanol) | Room air (no added fragrance) |
|---|---|---|
| What it is | Participants are exposed to 2-phenylethanol rose scent through an essential oil diffuser in their hospital room for 24 hours during epilepsy monitoring. | Participants are monitored in a hospital room with normal room air, without any added fragrance or olfactory intervention, for 24 hours. |
| Role in the trial | Evaluated as the investigational neuromodulatory intervention for possible effect on ictal apnea during inpatient EEG in epilepsy. | Serves as the control/reference condition, reflecting baseline monitoring without olfactory exposure. |
| Primary use or intended effect | Studied for potential to reduce the number of ictal and associated apneic episodes detected during continuous EEG in adults with epilepsy. | Serves as a measure of seizure and apnea frequency under normal monitoring conditions for baseline comparison. |
| How it is given or performed | Three drops of 2-phenylethanol (rose scent) are placed in an electronic diffuser in the patient’s room and continuously vaporized over 24 hours during EEG monitoring. | Participants remain in their hospital room breathing normal, unmodified room air during EEG observation. |
| Evidence maturity or published evidence | Non-invasive sensory neuromodulation approaches, including olfactory stimulation, are being researched for seizure modulation, but robust clinical evidence for rose scent preventing ictal apnea or SUDEP is not established. Limited small studies suggest feasibility of olfactory interventions for seizure management. | Representing usual care, room air exposure does not provide active neuromodulation; it serves as baseline monitoring for seizure and apnea frequency in current clinical practice. |
| Important limitations | Efficacy in preventing ictal apnea or reducing SUDEP risk is unestablished; findings from a small inpatient monitoring population may not generalize to outpatient or chronic epilepsy management. | Control condition does not include any therapeutic neuromodulation; results may not reflect possible effects of other sensory interventions or therapies used outside monitoring units. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - 24 hours
Participants undergo 24 hours of routine inpatient EEG monitoring while wearing a respiratory belt to measure breathing without any scent exposure in the room.
Continuous monitoring during hospital stay
Duration - 24 hours
Participants continue inpatient EEG monitoring for 24 hours while exposed to continuous rose scent diffused in their room and wearing the respiratory belt to measure breathing.
Continuous monitoring during hospital stay
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
CROSSOVER
Primary Purpose
PREVENTION
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Ariane E Rhone, Christopher K Kovach, Gail Is Harmata...
https://pubmed.ncbi.nlm.nih.gov/32163374/Teri B O'Neal, Sanjay Shrestha, Harsimar Singh...
https://pubmed.ncbi.nlm.nih.gov/35893283/Minh Q Nguyen, Nicholas J P Ryba
https://pubmed.ncbi.nlm.nih.gov/22848650/Pamela A Valentine, Sonja L Fremit, G Campbell Teskey
https://pubmed.ncbi.nlm.nih.gov/16039062/Zhongxia Li, Liying Chen, Cenglin Xu...
https://pubmed.ncbi.nlm.nih.gov/36813206/Ayako Motoki, Naoki Akamatsu, Tomoyuki Fumuro...
https://pubmed.ncbi.nlm.nih.gov/34775249/Mariana S Lunardi, Katia Lin, Rūta Mameniškienė...
https://pubmed.ncbi.nlm.nih.gov/27344500/William P Nobis, Karina A González Otárula, Jessica W Templer...
https://pubmed.ncbi.nlm.nih.gov/30952127/Yasin Yilmaz, Bengi Gul Turk, Merve Hazal Ser...
https://pubmed.ncbi.nlm.nih.gov/36066675/Vanderbilt University Medical Center
Lead Sponsor